Effects Criteria Definitions and Effects of Placebo and Efalizumab 1mg/kg/wk from the Wave 1 Case Study Report Efalizumab. Placebo Patient Fixed Fixed Efalizumab Name Description Source Units (pts population Lower† Upper† 1mg/kg/wk number) (pts number) PASI75* ACD2390g Moderate to Percentage of patients achieving 75% severe plaque reduction in baseline PASI at week 12 psoriasis 4.3 26.6 0 100 % The PASI is a measure of the average redness, candidate for (175) (345) thickness, and scaliness of the lesions (each systemic graded on a 0–4 scale), weighted by the area treatment of involvement ACD2058g 2.4 38.9a “ 0 100 % (151) (149) ACD2059g 4.9 22.4 a “ 0 100 % (111) (211) ACD2600g 3.0 23.5 a “ effects 0 100 % (236) (450) IMP24011 Moderate to severe plaque psoriasis Favourable 4.2 candidate for (264) 31.4 a systemic (529) treatment 0 100 % 29.5(342) 2.7(184) + need” “high subgroup
Effects Criteria Definitions and Effects of Placebo and Efalizumab 1mg/kg/wk from the Wave 1 Case Study Report Efalizumab. Name Description Source Patient population Fixed Lower† Fixed Upper† Units Placebo (pts number) Efalizumab 1mg/kg/wk (pts number) Favourable effects PASI75* Percentage of patients achieving 75% reduction in baseline PASI at week 12 The PASI is a measure of the average redness, thickness, and scaliness of the lesions (each graded on a 0–4 scale), weighted by the area of involvement ACD2390g Moderate to severe plaque psoriasis candidate for systemic treatment 0 100 % 4.3 (175) 26.6 (345) ACD2058g “ 0 100 % 2.4 (151) 38.9a (149) ACD2059g “ 0 100 % 4.9 (111) 22.4 a (211) ACD2600g “ 0 100 % 3.0 (236) 23.5 a (450) IMP24011 Moderate to severe plaque psoriasis candidate for systemic treatment + “high need” subgroup 0 100 % 4.2 (264) 2.7(184) 31.4 a (529) 29.5(342)
Download_ProACTURL_EffectsTable.docx